Skip to main content
SpringerLink
Log in

Anthracycline cardiotoxicity and lymphoma

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

Anthracyclines have substantially improved the prognosis of patients with aggressive lymphoma. Increased risk of cardiotoxicity is a significant concern associated with the use of anthracyclines, particularly in patients with pre-existing heart disease, elderly or very young patients, and those with established risk factors. A prolonged infusional schedule may alleviate the toxicity, but is difficult to implement in clinical practice. The administration of dexrazoxane, a cardioprotective agent, may ameliorate cardiotoxicity associated with anthracyclines. However, it has come under scrutiny because of increased risk of hematological second malignancies particularly in children. Liposomal doxorubicin is a viable alternative with less cardiotoxicity and similar efficacy than conventional doxorubicin. Patients should be screened for heart disease and known risk factors before initiating therapy. Risk factors should be adequately controlled and alternatives should be explored in patients at risk for cardiac toxicity. Survivorship care is an integral part of treatment, and patients should be monitored for late effects of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976 Oct;38(4):1484–93.

    Article  PubMed  CAS  Google Scholar 

  2. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10(1):337.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  3. Von Hoff DD, Layard MW, Basa P, Davis HLJ, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicininduced congestive heart failure. Ann Intern Med. 1979 Nov;91(5):710–7.

    Article  PubMed  CAS  Google Scholar 

  4. Moser EC. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood. 2006 Apr 1;107(7):2912–9.

    Article  PubMed  CAS  Google Scholar 

  5. Hequet O. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol. 2004 May 15;22(10):1864–71.

    Article  PubMed  CAS  Google Scholar 

  6. Moser EC, Noordijk EM, Carde P, Tirelli U, Baars JW, Thomas J, et al. Late non-neoplastic events in patients with aggressive non-Hodgkin’s lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials. Clin Lymphoma Myeloma. 2005 Sep;6(2):122–30.

    Article  PubMed  Google Scholar 

  7. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol. 1998 Aug; 25(4 Suppl. 10):72–85.

    PubMed  CAS  Google Scholar 

  8. Ng AK, LaCasce A, Travis LB. Long-term complications of lymphoma and its treatment. J Clin Oncol. 2011 May 10;29(14):1885–92.

    Article  PubMed  Google Scholar 

  9. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jan 24;346(4):235–42.

    Article  PubMed  CAS  Google Scholar 

  10. Limat S. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2003 Feb 1;14(2):277–81.

    Article  PubMed  CAS  Google Scholar 

  11. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006 May;7(5):379–91.

    Article  PubMed  CAS  Google Scholar 

  12. Aleman BMP, van den Belt-Dusebout AW, De Bruin ML, van ’t Veer MB, Baaijens MH, de Boer JP, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007 Mar 1;109(5):1878–86.

    Article  PubMed  CAS  Google Scholar 

  13. van Dalen EC, van der Pal HJ, Caron HN, Kremer LC. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev. 2009;(4):CD005008.

  14. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2005;(1):CD003917.

  15. Osby E. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood. 2003 May 15;101(10):3840–8.

    Article  PubMed  CAS  Google Scholar 

  16. Pettengell R, Coiffier B, Narayanan G, de Mendoza FH, Digumarti R, Gomez H, Zinzani PL, Schiller G, Rizzieri D, Boland G, Cernohous P, Wang L, Kuepfer C, Gorbatchevsky I, Singer JW. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2012 Jul;13(7):696–706.

    Article  PubMed  CAS  Google Scholar 

  17. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2008;(2):CD003917.

  18. Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol. 2007 Feb;25(5):493–500.

    Article  PubMed  CAS  Google Scholar 

  19. Walker DM, Fisher BT, Seif AE, Huang YS, Torp K, Li Y, et al. Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the Pediatric Health Information Systems database. Pediatr Blood Cancer. 2013 Apr;60(4):616–20.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Minotti G. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004 Jun 1;56(2):185–229.

    Article  PubMed  CAS  Google Scholar 

  21. Mross K, Niemann B, Massing U, Drevs J, Unger C, Bhamra R, et al. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. Cancer Chemother Pharmacol. 2004 Dec;54(6):514–24.

    Article  PubMed  CAS  Google Scholar 

  22. Kanter PM, Bullard GA, Ginsberg RA, Pilkiewicz FG, Mayer LD, Cullis PR, et al. Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. In Vivo. 1993 Jan;7(1):17–26.

    PubMed  CAS  Google Scholar 

  23. Kanter PM, Bullard GA, Pilkiewicz FG, Mayer LD, Cullis PR, Pavelic ZP. Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): comparison with doxorubicin and empty liposomes in mice and dogs. In Vivo. 1993 Jan;7(1):85–95.

    PubMed  CAS  Google Scholar 

  24. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002 Jan 1;94(1):25–36.

    Article  PubMed  CAS  Google Scholar 

  25. Tulpule A, Espina BM, Berman N, Buchanan LH, Smith DL, Sherrod A, et al. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin’s lymphoma. Clin Lymphoma Myeloma. 2006 Jul;7(1):59–64.

    Article  PubMed  CAS  Google Scholar 

  26. Levine AM, Tulpule A, Espina B, Sherrod A, Boswell WD, Lieberman RD, et al. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin’s lymphoma: results of therapy and correlates of response. J Clin Oncol. 2004 Jul;22(13):2662–70.

    Article  PubMed  CAS  Google Scholar 

  27. Visani G, Ferrara F, Alesiani F, Ronconi S, Catarini M, D’adamo F, et al. R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study. Leuk Lymphoma. 2008 Jun;49(6):1081–6.

    Article  PubMed  CAS  Google Scholar 

  28. Luminari S, Montanini A, Caballero D, Bologna S, Notter M, Dyer MJ, et al. Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. Ann Oncol. 2010 Jul;21(7):1492–9.

    Article  PubMed  CAS  Google Scholar 

  29. Rigacci L, Mappa S, Nassi L, Alterini R, Carrai V, Bernardi F, et al. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. Hematol Oncol. 2007 Dec;25(4):198–203.

    Article  PubMed  CAS  Google Scholar 

  30. Corazzelli G, Frigeri F, Arcamone M, Lucania A, RosariaVilla M, Morelli E, et al. Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high “life threat” impact cardiopathy. Br J Haematol. 2011 Sept;154(5):579–89.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  31. Alberts DS, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, et al. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol. 2004 Dec;31(6 Suppl. 13):53–90.

    Article  PubMed  CAS  Google Scholar 

  32. Fridrik M, Petzer A, Keil F, Willenbacher W, Jäger U, Lang A, et al. Non-pegylated liposomal doxorubicin reduces cardiotoxicity in 1st line treatment of diffuse large B-cell lymphoma (DLBCL). Final results of a randomized trial. ASH Annu Meet Abstr. 2011;118(21):2676–6.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internal Medicine 3, Center for Hematology and Medical Oncology, General Hospital of Linz, Krankenhausstrasse 9, 4020, Linz, Austria

    David Mayr MD & Michael A. Fridrik MD

Authors
  1. David Mayr MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael A. Fridrik MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael A. Fridrik MD.

Additional information

This material was orally presented at the Congress of the Austrian Association for Hematology and Oncology (ÖGHO) in Linz, Austria, in March 2013.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mayr, D., Fridrik, M. Anthracycline cardiotoxicity and lymphoma. memo 7, 43–46 (2014). https://doi.org/10.1007/s12254-013-0128-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-013-0128-2

Keywords

Search

Navigation